Viruses for the treatment of cellular proliferative disorders
AssigneeOncolytics Biotech Inc.
InventorsMatthew C. Coffey, Bradley G. Thompson
Life of this patent
Estimating the term…
Abstract
Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent.
Claims28
A method for treating a Ras-mediated cell proliferative disorder in a mammal, comprising the steps of:
- (a) selecting a mammal with a ras-mediated cell proliferative disorder comprising cells having an activated ras-pathway, wherein activation of PKR is blocked in the cells;
- and
- (b) administering to the cells an effective amount of at least one modified vaccinia virus under conditions which result in substantial lysis of the proliferating cells, wherein the vaccinia virus comprises a mutant gene selected from the group consisting of E3L and K3L.
A method of treating a neoplasm having an activated Ras-pathway in a human, comprising the steps of:
- (a) selecting a human with a neoplasm comprising cells having an activated Ras-pathway, wherein activation of PKR is blocked in the cells;
- and
- (b) administering to the cells an effective amount of at least one modified vaccinia virus, to result in substantial oncolysis of the cells, wherein the vaccinia virus comprises a mutant gene selected from the group consisting of E3L and K3L.
A method of inhibiting metastasis of a neoplasm having an activated Ras-pathway in a mammal, comprising the steps of:
- (a) selecting a mammal with a neoplasm comprising neoplastic cells having an activated Ras-pathway, wherein activation of PKR is blocked in the neoplastic cells;
- and
- (b) administering to the neoplastic cells in the mammal at least one modified vaccinia virus, in an amount sufficient to result in substantial lysis of the neoplastic cells, wherein the vaccinia virus comprises a mutant gene selected from the group consisting of E3L and K3L.
Dependencies are inferred from the claim text.